Averin Capital Acquisition Corp.

Averin Capital Acquisition Corp. (ACAAU) reported a net income of $2.36 million for the three months ended June 30, 2026, and $3.19 million for the six months ended June 30, 2026, primarily from interest earned on its Trust Account. As of June 30, 2026, the company held $287.37 million in its Trust Account. However, management has identified substantial doubt about the company's ability to continue as a going concern due to a lack of liquidity and the uncompleted business combination.

Averin Capital Acquisition Corp. appointed Akiko Moni Miyashita to its Board of Directors, effective May 28, 2026. Ms. Miyashita brings over 25 years of experience in strategy, finance, and corporate development, with expertise in healthcare, life sciences, technology, and global markets. Her background includes founding Beacon Hill Strategy Group, serving on the board of Halozyme Therapeutics, and executive roles at Valo Health, McKinsey & Company, Innosight LLC, and IBM. In connection with her appointment, she entered into standard director agreements, including a joinder to a Letter Agreement and a Registration Rights Agreement.

Averin Capital Acquisition Corp. reported a net income of $832,500 for the three months ended March 31, 2026, primarily from interest earned on its Trust Account. The company completed its Initial Public Offering and a Private Placement, raising $283,860,080 which was subsequently placed into a Trust Account. Despite the income, management identified substantial doubt about the company's ability to continue as a going concern due to its early stage and the requirement to complete a Business Combination within the specified period.

Averin Capital Acquisition Corp. (ACAAU) announced that holders of its units will be able to elect to separately trade the Class A ordinary shares and warrants starting April 10, 2026. Each unit, currently trading under "ACAAU" on the Nasdaq Global Market, consists of one Class A ordinary share and one-sixth of one redeemable warrant. Following the separation, the Class A ordinary shares are expected to trade under "ACAA" and the warrants under "ACAAW" on the Nasdaq Global Market. This move provides investors with increased flexibility to trade the equity and derivative components of the units independently, which is a standard procedural step for SPACs post-IPO.